After Dobbs, 42 Percent of Surveyed Abortion Providers in Abortion-Ban States Relocated
By Elana Gotkine HealthDay Reporter

TUESDAY, June 17, 2025 -- Following the Dobbs v Jackson Women’s Health Organization (2022) decision, 42 percent of surveyed clinicians who provided abortions in states banning abortion relocated to another state, almost all to states not banning abortion, according to a research letter published online June 11 in JAMA Network Open.
Dana Howard, Ph.D., from The Ohio State University College of Medicine in Columbus, and colleagues recruited clinicians who provided abortion the year before Dobbs and/or at the time of the survey to examine the proportion of abortion-providing clinicians who changed their primary state of practice.
The analytic sample included 305 respondents. The researchers found that 91 percent of respondents reported providing some nonabortion health care. Overall, 74 and 26 percent of participants practiced in no-ban states and ban states before Dobbs, respectively. Forty-seven respondents (16 percent) relocated their primary practice state; clinicians practicing in states that would ban abortion were much more likely to relocate than those in no-ban states (27 versus 20 respondents [42 versus 9 percent]). Most of those who relocated from ban states relocated to no-ban states (89 percent of 27 respondents). Most of those who relocated from no-ban states relocated to another no-ban state (90 percent of 20 respondents). Six percent of respondents stopped providing any abortion care after Dobbs.
"Given that most study respondents provided both abortion and nonabortion health care, these accelerated relocations have implications for abortion access and for the broader maternal health workforce, exacerbating health care deserts and outcome disparities," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-06-18 06:00
Read more

- Marine Microplastic Levels Linked to Cardiometabolic Disease Prevalence
- Worse Outcomes Seen for Unvaccinated Patients Hospitalized With COVID-19, AKI
- Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
- Smartphone App Can Track Huntington's Disease Symptoms
- Higher Dose of Wegovy Provided Average Weight Loss of 21% in People with Obesity With a Third Achieving 25% or More
- Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions